International Business Opportunity of "Sun Pharmaceuticals Company"

1. S.R. Luthra Inatitute of Management

2. International Business Opportunity of
“Sun pharmaceuticals company”
Presented to –
Mr. Harshesh Patel,
Assistant Professor
Mr. Imran Shaik,
Assistant Professor
Presented By-
Chaitya mehta-187500592061
Divyesh Mahale-187500592056
Jenish Modi-187500592063
Chanchal Jhanwar-187500592017

3. About Medicine Product
(Pharmexcil)

4. Region wise

5. Demand and supply scenario
• Indian pharmaceutical sector industry supplies
• over 50 per cent of global demand
• 40 per cent of generic demand in the US
• 25 per cent of all medicine in UK
• Indian drugs are exported to more than 200 countries in the world,
with the US as the key market.
• Pharmaceutical exports from India, which include
• bulk drugs, intermediates,
• drug formulations, biologicals,
• Ayush & herbal products
• surgicals reached
• Medical devices industry in India has been growing 15.2 per cent annually and was valued
at US$ 5.2 billion in 2018 and is expected to reach US$ 50 billion by 2025.

6. Segment and sub-segment of industryor product

7. About Sun Pharmaceutical Company
• Established by Mr. Dilip
Sanghavi in 1983
in Vapi, Gujarat.
• Multinational Pharmaceutical
company.
• India’s Biggest Pharmaceutical
company.
• 75% of the sales is outside
the country.
• 60% of the revenue come
from outside India.
• USA is the major Importer.

8. Vision
Reaching People and Touching Lives Globally as a Leading Provider of
Valued Medicines
Mission
Sunology - a combination of two words, Sun & Ideology is at the core
of Sun. Humility, Integrity, Passion & Innovation together form
Sunology. It is a way of life at Sun.

9. Sun Pharmaceutical Industries Ltd.
Address
SUN HOUSE,
CTS No. 201 B/1,
Western Express Highway,
Goregaon (E),
Mumbai 400063
Telephone (+91 22) 4324 4324
Fax (+91 22) 4324 4343

10. Product portfolio
• specialty and generic products targeting a wide
spectrum of chronic and acute treatments.
• Technology-based differentiation and cover the
full range of dosage forms, including tablets,
capsules, injectables, inhalers, ointments,
creams and liquids.

11. Some products of Sun Pharma
BRAND NAME GENERIC NAME THERAPEUTIC SEGMENT
REVITAL H
Ginseng, Vitamins and
Minerals
VMS-Vitamins, Minerals and
Supplements
REVITAL H WOMAN
Ginseng, Vitamins and
Minerals (Specially
formulated for women)
VMS-Vitamins, Minerals and
Supplements
VOLINI GEL Pain Relief Gel ANALGESIC-Topical
VOLINI SPRAY Pain Relief Spray ANALGESIC-Topical
VOLINI ACTIV GEL Herbal Pain Relief Gel ANALGESIC-Topical
VOLINI ACTIV SPRAY Herbal Pain Relief Spray ANALGESIC-Topical
ABZORB
Clotrimazole 1% Dusting
Powder
Antifungal Dusting Powder
PEPFIZ
Effervescent Digestive
Enzymes
GI-Gastrointestinal
GARLIC PEARLS Garlic Oil Cholesterol control
OLESAN OIL Nasal decongestant CCA-Cough, Cold & Allergy

12. Sun Pharma Industries SWOTAnalysis
Strength Weakness
1. Strong growth in emerging market business
2. Introduction of Pantoprazole & Eloxatin in US
market has very limited competition
3. They have strong marketing & sales force of
over 12,000 employees
4. They have successfully acquired Taro pharma
which has further consolidated their position in
Indian markets
5. Strong brand presence in India and US markets
1. Stiff competition from many Indian
and other global brands means limited
market share growth
2. Limited presence in emerging
markets and European countries
Opportunities Threats
1. They can leverage their acquisitions to
further increase the growth
2. They can increase their presence in
contract manufacturing
3. Increasing healthcare awareness in India
1. There is growing competition in
generics market
2. Stringent patent regulations
3. High price sensitivity of consumers

13. Competitive Environment
• The Threat of New Entrant:
• Many new companies to enter the market without burden of costly tasks such as
research and development, clinical trials and manufacturing of drugs.
• The government has increased their focus on healthcare cost cutting buy which
government provide permission to the manufacturers.
• The Threat of Substitutes
• Generic manufacturers do not incur the high cost involved in research and
development and regulatory activities such as FDA approval and clinical trials.
• Bargaining Power of Buyers:
• The buyer's bargaining power is moderate.
• Bargaining Power of Suppliers:
• The bargaining power of suppliers in market is low. Pharmaceutical products
require various types of organic chemical.
• The Intensity of the Competitive Rivalry:
• The presence of a number of large and small firm this market is highly
competitive.

14. About United States of America
• The United States of America is the world's third largest country in size and nearly the third
largest in terms of population.
Languages:
• English, Spanish (no official national language)
Money:
• U.S dollar
Exchange rate:
• 1 United States Dollar equals 71.09 Indian Rupee
Religion:
• Religion in the United States is diverse with Christianity being the majority religion
National Anthem
• "The Star-Spangled Banner" is the national anthem of the United States.
Ruling party:
• the Republican Party and the Democratic Party.

15. Bilateral trade opportunity with India and United
States
Export
• India was the United States' 13th largest goods export market in 2018.
• U.S. goods exports to India in 2018 were $33.1 billion
• U.S. total exports of agricultural products to India totaled $1.5 billion in 2018
• U.S. exports of services to India were an estimated $25.8 billion in 2018
Imports
• India was the United States' 10th largest supplier of goods imports in 2018.
• U.S. goods imports from India totalled $54.4 billion in 2018
• U.S. total imports of agricultural products from India totalled $2.7 billion in 2018
• U.S. imports of services from India were an estimated $28.8 billion in 2018,

16. About Selected Modes of Entry
Acquisition and join venture
• 1996, purchased Halol and knoll from USA.
• 1997, Dadha Pharmaceuticals Limited (TDPL) based in Chennai.
• acquisition of Caraco Pharmaceuticals, based in Detroit.
• acquired a large stake in Taro Pharmaceuticals
• 2011, joint venture with MSD
• 2012, acquisitions of two US companies: DUSA Pharmaceuticals,
generic pharma company URL Pharma.
• 2013, R&D joint venture for ophthalmology with the research
company, Intrexon.
• 2015, agreed to buy GlaxoSmithKline's opiates
• business in Australia to strengthen its pain management portfolio

17. Sun Pharma STP
Segment
Cardiology, psychiatry, neurology, gastroenterology,
dibetology
Target Group Healthcare professionals, pharmacists
Positioning
They are international specialty pharma company
with
strong presence in Indian & US generics market

18. 4 P’s
Product
• Both pharmaceuticals and active
pharmaceutical.
• Major focus on the growing chronic
therapies.
• Generic medicines
• Both Ayurvedic and Allopatic
Price
• Reasonable pricing strategy
• Optimise the operational cost
• Generic medicines at a very low cost
• Patents help to get profit
Place
• Around 19 manufacturing plants in
almost 6 continents.
• Successfully serving patients in around
150 nations
Promotion
• Focuses on reaching the customers
everywhere.
• focusses on reaching the customers
everywhere
• sponsoring programmes and hoardings
etc.
• attractive offers and schemes

19. Staffing Strategy
Designing the workforce plan for the organization:
• Identifying and institutionalizing manning norms for
different roles at our manufacturing plants (both SGO and
API), R&D centers and for the corporate functions.
• Calculate and manage the annual financial implication of
proposed manpower.
• Carry out internal & external studies along with review of
the existing manpower, benchmark with similar plants,
identification of gaps and providing recommendations on
proposed manpower.
• Training the location HR team to use this process to
create future work plans for their respective locations,
based on future scenarios .

20. Set up the systems and processes to ensure compliance to the
workforce plan
• Set up processes to periodically monitor the progress of
each function vis-- -vis the workforce plan across all
locations and maintain the repository of organization charts
and the role directory for the organization
• Create a meaningful interpretation of the manpower data
of the organization data, using industry intelligence and
logic to frame situations and allow meaningful dialogue and
decision making for the top management
• Act as an approving authority in the recruitment workflow to
ensure that the recruitment is in line with the workforce plan

21. Identify opportunities for improving manpower productivity
and driving effective organization restructuring
• Study department work, vacation and absence records for on-
going historical trend analysis and offer recommendations for
forecasting purposes
• Identify areas for productivity improvement through
effective structuring of teams to eliminate duplication of
work, ensuring the right span of control and number of
layers
• Being a part of any other productivity improvement projects
which could be rolled out in the future

22. Supply Chain Management
Supply Chain Management process of Sun Pharma
1. The Suppliers
2. The Manufacturing Facilities
3. Central Warehouse
4. Distributors
5. Wholesalers, Hospitals and Retailers
6. End consumer

24. Financial Projection

26. Conclusion
There is an good scope of Sun pharma for in future in terms of
strong marketing, Employment, various acquisition, various
Patented products , growing exports, because of government
support and many more. So one can also invest in these
company. There is a good scope of Pharmaceutical industry
because government have aim to make india a pharmaceutical
products hub. There are many chance of growth in these
industry.

27. Thank You